Two‐year efficacy of SNK01 plus pembrolizumab for non‐small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial

BACKGROUND: A previous trial showed that autologous ex‐vivo expanded NK cell (SNK01) treatment combined with pembrolizumab showed better efficacy than pembrolizumab monotherapy in advanced non‐small cell lung cancer (NSCLC). This study was a 2‐year follow‐up of that previous study to determine the l...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hyung Jun, Kim, Yong Man, Jung, Jae Seob, Ji, Wonjun, Lee, Jae Cheol, Choi, Chang‐Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284127/
https://www.ncbi.nlm.nih.gov/pubmed/35670036
http://dx.doi.org/10.1111/1759-7714.14523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284127/
https://www.ncbi.nlm.nih.gov/pubmed/35670036
http://dx.doi.org/10.1111/1759-7714.14523

Ejemplares similares